Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome

BRCA mutations are associated with an increased risk of pancreatic cancer (PC). Olaparib, an oral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been approved for the treatment of metastatic PC with a germline BRCA mutation. In this report, we present the case of a metastatic P...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuneizumi, Michiko, Terada, Shuzo, Usui, Takeshi, Yamaguchi, Kei, Hayami, Ryosuke, Matsunuma, Ryoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693819/
https://www.ncbi.nlm.nih.gov/pubmed/36447463
http://dx.doi.org/10.1093/omcr/omac124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693819/
https://www.ncbi.nlm.nih.gov/pubmed/36447463
http://dx.doi.org/10.1093/omcr/omac124

Ejemplares similares